Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, TDS, WOM, TRI, FVT, DEI

Mammogen to Showcase New Data at SABCS 2023 Demonstrating Clinical Efficacy of Its genTRU-breasttm qPCR Blood Test in Early-Stage Breast Cancer


Groundbreaking data unveiled in San Antonio: CLIA validated genTRU-breast assay achieves >99% sensitivity in stage I breast cancer

NEWPORT BEACH, Calif., Dec. 1, 2023 /PRNewswire/ -- Mammogen, a pioneering leader in women's health and a subsidiary of early detection parent company, IVBH, is set to present groundbreaking clinical data at the 2023 San Antonio Breast Cancer Symposium (SABCS). The poster, titled "Development of a plasma-based real-time qPCR gene expression assay for targeted screening and diagnosis of early-stage breast cancer," showcases the strength and innovation of Mammogen's proprietary genTRU-breast clinical assay.

"The statistically significant >99% sensitivity and 89% specificity in stage I breast cancer, achieved during CLIA validation of our novel real-time qPCR assay, reinforces Mammogen's position as a leader in accurate, affordable, scalable, and socially responsible diagnostics in women's health." ?Elizabeth Cormier-May, CEO of Mammogen

Poster Session Details:

Presentation ID: PO1-28-06
Abstract Title: Development of a plasma-based real-time qPCR gene expression assay for targeted screening and diagnosis of early-stage breast cancer.
Session: Poster Session 1
Date: Wednesday, December 6, 2023
Time: 12:00 PM - 2:00 PM
Location: Henry B. Gonzalez Convention Center, San Antonio, Texas

This presentation follows Mammogen's successful CLIA validation of the genTRU-breast assay, announced last month, a landmark achievement for the company and a transformative milestone in early-stage breast cancer detection.

Elizabeth Cormier-May, CEO of Mammogen, commented, "This data is a testament to our commitment to unlocking the quality-of-life preservation that exists in the earliest stages of breast cancer. The statistically significant >99% sensitivity and 89% specificity in stage I breast cancer, achieved during CLIA validation of our novel real-time qPCR assay, reinforces Mammogen's position as a leader in accurate, affordable, scalable, and socially responsible diagnostics in women's health."

About Mammogen

Mammogen is a female-led precision diagnostics company dedicated to radically improving the detection, diagnosis and treatment of diseases that affect some, mostly or only women. Our flagship liquid detection program, genTRU-breast, is a CLIA validated PCR-based gene expression blood test designed to detect breast cancer in the earliest stages. The genTRU-breast assay is anticipated to launch commercially as a laboratory developed test (LDT) in 2H 2024. For more information, visit mammogen.bio.

About IVBH

IVBH is the world's first disease-agnostic AI-powered early detection platform, creating first-in-class blood tests that detect the body's response to disease in the earliest stages. With a mission to unlock the quality-of-life preservation at stage zero, IVBH provides highly accurate, affordable, and accessible diagnostic solutions for all of humanity. For more information, visit ivbh.studio.

For media inquiries, please contact: [email protected]

SOURCE Mammogen


These press releases may also interest you

at 21:05
Tricentis, a global leader in continuous testing and quality engineering, today announced the opening of its Japanese subsidiary, Tricentis Japan G.K. (hereinafter "Tricentis") situated in Chiyoda-ku, Tokyo, and the appointment of Ayumu Narizuka as...

at 21:05
Larsa Pippen, renowned influencer and entrepreneur, is proud to announce along with her Partner LeAnn Berman (Crupi) the launch of her revolutionary product, the "Larsa Light." Designed to revolutionize mobile photography, the Larsa Light is set to...

at 21:00
Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that, further to its press release dated February 28, 2024, it has...

at 20:50
Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its  underwritten public offering of 6,471,000...

at 20:30
TCL, a leading consumer electronics brand and the world's top two TV brands, participates Mobile World Congress 2024 in Barcelona to unveil its latest innovations and smart ecosystem of seamlessly connected devices designed to enhance the human...

at 20:03
Inc. magazine today revealed that Stratedia is No. 59 on its fourth annual Inc. 5000 Regionals: Northeast list, the most prestigious ranking of the fastest-growing Northeast private companies, based in Pennsylvania, New York, Vermont, New Hampshire,...



News published on and distributed by: